Analyzing R&D Budgets: Soleno Therapeutics, Inc. vs Celldex Therapeutics, Inc.

R&D Spending: Celldex vs. Soleno - A Decade of Innovation

__timestampCelldex Therapeutics, Inc.Soleno Therapeutics, Inc.
Wednesday, January 1, 20141043810002242216
Thursday, January 1, 20151001710004536244
Friday, January 1, 20161027260005184803
Sunday, January 1, 2017961710003068742
Monday, January 1, 2018664490007178000
Tuesday, January 1, 20194267200016267000
Wednesday, January 1, 20204253400023191000
Friday, January 1, 20215331100021453000
Saturday, January 1, 20228225800015265000
Sunday, January 1, 202311801100025189000
Loading chart...

Unlocking the unknown

A Decade of R&D Investment: Soleno vs. Celldex

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Celldex Therapeutics, Inc. and Soleno Therapeutics, Inc. have demonstrated contrasting R&D investment strategies.

From 2014 to 2023, Celldex consistently outpaced Soleno, with R&D expenses peaking at approximately $118 million in 2023, a 178% increase from its lowest point in 2019. In contrast, Soleno's R&D spending, while more modest, showed a significant upward trend, culminating in a 102% increase from 2014 to 2023.

This divergence highlights Celldex's aggressive pursuit of innovation, while Soleno's steady growth reflects a more cautious approach. As the biotech industry continues to evolve, these investment patterns may offer insights into each company's future trajectory and potential breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025